4 курс / Акушерство и гинекология / Гиперплазия_эндометрия_Доброхотова_Ю_Э_,_Сапрыкина_Л_В_,_2018_г_

92.Granberg S., Wikland M., Karlsson B.et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality // Am. J. Obstet. Gynecol. 1991. Vol. 164. P. 47-52.

93.Grimes D.A. Diagnostic dilation and curettage: a reappraisal // Am. J. Obstet. Gynecol. 1982. Vol. 142. P. 1-6.

94.Gruboeck K., Jurkovic D., Lawton F. et al. The diagnostic value of endometrial thickness and volume measurements by three-dimensional ultrasound in patient with postmenopausal bleeding // Ultrasound Obstet. Gynecol. 1996. Vol. 8. P. 272-276.

95.Guidelines on Clinical Management of Endometrial Hyperplasia. HKCOG Guidelines No. 16. Sept. 2015.

96.Guruwadayarhalli B., Jones S.E., Srinivasan V. Hysteroscopy in the diagnosis of postmenopausal bleeding // Menopause Int. 2007. Vol. 13, N. 3. P. 132-134.

97.Haabeth O.A., Bogen B., Corthay A. A model for cancer-suppressive inflammation // Oncoimmunology. 2012. Vol. 1, N. 7. P. 1146-1155.

98.Hammond S.B. Menopause and hormone replacement therapy // Obstet. Gynecol. 1996. Vol. 87, N. 2. P. 15.

99.Inoue M. Current molecular aspects of the carcinogenesis of the uterine endometrium // Int. J. Gynecol. Cancer. 2001. Vol. 11. Р. 339-348.

100.Ishikawa M., Nakayama K., Yeasmin S. et al. NAC1, a potential stem cell pluripotency factor expression in normal endometrium, endometrial hyperplasia and endometrial carcinoma // Int. J. Oncol. 2010. Vol. 36, N. 5. P. 1097-1103.

101.Järvelä I.Y., Santala M. Treatment of non-atypic endometrial hyperplasia using thermal balloon endometrial ablationtherapy // Gynecol. Obstet. Invest. 2005. Vol. 59, N. 4. P. 202-206.

102.Kaaks R., Lukanova A., Kurzer M.S. Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review // Cancer Epidemiol. Biomar. Prev. 2002. Vol. 11. P. 1531-1543.

103.Kim J.J., Chapman-Davis E. Role of progesterone in endometrial cancer // Semin. Reprod. Med. 2010. Vol. 28, N. 1. P. 81-90.

104.Kolodziejczak M., Knapp P., Kuzmicki M., Knapp P. Current possibilities of examination and preservative treatment in endometrial hyperplasia // Ginekol. Pol. 2011. Vol. 82, N. 7. P. 514-519.

Медицинские книги

@medknigi

105.Kurman R.J., Kaminski P.F., Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients // Cancer. 1985. Vol. 56. P. 403-412.

106.La Sala G.B., Blasi I., Gallinelli A. et al. Diagnostic accuracy of sonohysterography and transvaginal sonography as compared with hysteroscopy and endometrial biopsy: a prospective study // Minerva Ginecol. 2011. Vol. 63, N. 5. P. 421-427.

107.Lee S.Y., Kim M.K., Park H. et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women // J. Gynecol. Oncol. 2010. Vol. 21, N. 2. P. 102-105.

108.Lethaby A., Vollenhoven B., Sowter M.C. Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids // Cochrane Database Syst. Rev. 2001. Vol. 2. CD000547.

109.Li L., Bing L., Ying Zh. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia // Cochrane Database Syst. Rev. 2013. Vol. 6. CD009458.

110.Litta P., Bartolucci C., Saccardi C. et al. Atypical endometrial lesions: hysteroscopic resection as an alternative to hysterectomy // Eur. J. Gynaecol. Oncol. 2013. Vol. 34, N. 1. P. 51-53.

111.Long-Term Consequences of Polycystic Ovary Syndrome. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 33. London : RCOG; 2014.

112.Lowdell M.W. Natural Killer T cells - balancing the regulation oftumor immunity // Br. J. Cancer. 2012. Vol. 107, N. 10. P. 1795-1796.

113.Majumdar A., Singh T.A. Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome // J. Hum. Reprod. Sci. 2009. Vol. 2, N. 1. P. 12-17.

114.Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview // Front. Biosci. 2006. Vol. 11. P. 1696-1701.

115.Management of Endometrial Hyperplasia. RCOG/ BSGE Joint Guideline. February 2016. Green-top Guideline No. 67. 31 p.

116.Marnach M.L., Butler K.A., Henry M.R. et al. Oral progestogens versus levonorgestrel-releasing intrauterine system for treatment of endometrial intraepithelial neoplasia // J. Womens Health (Larchmt). 2017. Vol. 26, N. 4. Р. 368-373.

Медицинские книги

@medknigi

117.Michalek R.D., Gerriets V.A., Nichols A.G. et al. Estrogen-related receptor- α is a metabolic regulator of effector T-cell activation and differentiation // Proc. Natl Acad. Sci. USA. 2011. Vol. 108, N. 45. P. 18 348-18 353.

118.Minig L., Franchi D., Boveri S. et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women // Ann. Oncol. 2011. Vol. 22, N. 3. P. 643-649.

119.Moradan S., Ghorbani R., Lotfi A. Agreement of histopathological findings of uterine curettage and hysterectomy specimens in women with abnormal uterine bleeding // Saudi Med. J. 2017. Vol. 38, N. 5. Р. 497-502.

120.Munakata S., Sasaki S., Takase M. et al. Practical usefulness of atypical endometrial cell categories within the new classification of endometrial cytology when applied to conventional smears // Cytopathology. 2017. Vol. 28, N. 2. P. 131-139.

121.Munoz-Cruz S., Togno-Pierce C., MoralesMontor J. Non-reproductive effects of sex steroids: their im-

munoregulatory role // Curr. Top. Med. Chem. 2011. Vol. 11, N. 13. P. 17141727.

122.Nemejcova K., Rosmusova J., Bartu M. et al. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases // Int. J. Surg. Pathol. 2017. Vol. 25, N. 5. P. 389-396.

123.Oleinika K., Nibbs R.J., Graham G.J., Fraser A.R. Suppression, subversion and escape: the role of regulatory T cells in cancer progression // Clin. Exp. Immunol. 2013. Vol. 171, N. 1. P. 36-45.

124.Orbo A., Arnes M., Hancke C., Vereide A.B. et al. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only // Gynecol. Oncol. 2008. Vol. 111. P. 68-73.

125.Orbo А., Vereide А.В., Arnes М. et al. Levonorgestrelimpregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial // BJOG. 2014. Vol. 121, N. 4. P. 477-486.

126.Otify M., Fuller J., Ross J. Endometrial pathology in the postmenopausal woman - an evidence based approach to management // Obstetrician Gynaecologist. 2015. Vol. 17, N. 1. P. 29-38.

127.Patel V., Wilkinson E.J., Chamala S. et al. Endometrial thickness as measured by transvaginal ultrasound and the corresponding histopathologic

Медицинские книги

@medknigi

diagnosis in women with postmenopausal bleeding // Int. J. Gynecol. Pathol. 2017. Vol. 36, N. 4. Р. 348-355.

128.Peggs K.S., Quezada S.A. PD-1 blockade: promoting endogenous antitumor immunity // Expert Rev. Anticancer. Ther. 2012. Vol. 12, N. 10. P. 12791282.

129.Perino A., Quartararo P., Catinella E. et al. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices // Acta Eur. Fertil. 1987. Vol. 18, N. 2. P. 137-140.

130.Randall T.C., Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the

endometrium in women under age 40 // Obstet. Gynecol. 1997. Vol. 90. P. 434-440.

131.Reed S.D., Newton K.M., Garcia R.L. et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy // Obstet. Gynecol. 2010. Vol. 116, N. 2. Pt. 1. P. 365-373.

132.Reed S.D., Newton K.M., Clinton W. et al. Incidence of endometrial hyperplasia // Am. J. Obstet. Gynecol. 2009. Vol. 200, N. 6. P. 678e1-678e6.

133.Rudnicka E., Wierzba W., Radowicki S. Evaluation of endometrial histologic morphology in patients with polycystic ovary syndrome // Ginekol. Pol. 2009. Vol. 80, N. 2. P. 103-106.

134.Sabbioni L., Petraglia F., Luisi S. Non-contraceptive benefits of intrauterine levonorgestrel administration: why not? // Gynecol. Endocrinol. 2017. Vol. 5. P. 1-8.

135.Sckisel G.D., Murphy W.J. Specificity may be overrated in cancer immunotherapy: getting to know the nonspecific side of memory T cells // Oncoimmunology. 2012. Vol. 1, N. 7. P. 1208-1210.

136.Scottish Intercollegiate Guidelines Network (SIGN). Investigation of PostMenopausal Bleeding. SIGN Publication No. 61. Edinburgh : SIGN, 2002.

137.Scully R.E., Bonfiglio T.A., Kurman R.J. et al. World Health Organization. Histologic Typing ofTumors ofthe Female Genital Tract. Heidelberg : SpringerVerlag, 1994. 2628 p.

138.Shindler A.E. Progestins and the endometrium // Zentralbl. Gynakol. 1997. Vol. 2. P. 59-63.

139.Silverberg S.G., Kurman R.J., Nogales F., Mutter G.L. et al. Epithelial tumours and related lesions // Pathology and Genetics of Tumours of the

Медицинские книги

@medknigi

Breast and Female Genital Organs. World Health Organization Classification of Tumours / eds F.A. Tavassoli, P. Devilee. Lyon : IARC Press, 2003. P. 221-232.

140.Sowter M.C., Lethaby A., Singla A. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding // Cochrane Database Syst. Rev. 2002. Vol. 2. CD001124.

141.Suidan R.S., He W., Sun C.C. et al. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia // Gynecol. Oncol. 2017. Vol. 145, N. 1. Р. 55-60.

142.Supracervical hysterectomy. ACOG Committee Opinion No. 388 // Obstet. Gynecol. 2007. Vol. 110. P. 1215-1217.

143.Sweet M.G., Schmidt-Dalton T.A., Weiss P.M., Madsen K.P. Evaluation and management of abnormal uterine bleeding in premenopausal women // Am. Fam. Physician. 2012. Vol. 85, N. 1. P. 35-43.

144.Tanos V., Berry K.E., Seikkula J. The management of polyps in female reproductive organs // Int. J. Surg. 2017. Vol. 43. P. 7-16.

145.Uysal G., Acmaz G., Madendag Y. The efficacy of dienogest in the treatment of simple endometrial hyperplasia without atypia // Gynecol. Obstet. Invest. 2017. Vol. 15. doi: 10.1159/000477618.

146.van der Meer A.C., Hanna L.S. Development of endometrioid adenocarcinoma despite levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia // Clin. Obes. 2017. Vol. 7, N. 1. Р. 54-57.

147.Varma R., Soneja H., Bhatia K., Ganesan R. et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia - a long-term follow-up study // Eur. J. Obstet.

Gynecol. Reprod. Biol. 2008. Vol. 139. P. 169-175.

148.Vereide A.B., Kaino T., Sager G. et al. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia // Gynecol. Oncol. 2006. Vol. 101, N. 2. P. 214-

149.Waksmanski B., Dudkiewich J., Dabrowski S. Function of insulin-like grown factor (IGF-I) and its binding protein (IGFBP-I) in pathological proliferation of endometrium // Wiad. Lec. 2001. Vol. 54. P. 656-661.

Медицинские книги

@medknigi

150.Wartko P.D., Beck T.L., Reed S.D. et al. Association of endometrial hyperplasia and cancer with a history of gestational diabetes // Cancer Causes Control. 2017. Vol. 28, N. 8. Р. 819-828.

151.Wheeler D.T., Bristow R.E., Kurman R.J. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins // Am. J. Surg. Pathol. 2007. Vol. 31. P. 988-998.

152.Wildemeersch D., Janssens D., Pylyser K., De Wever N. et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up // Maturitas. 2007. Vol. 57. P. 210-213.

153.Wolfman W., Leyland N., Heywood M. et al. Society of Obstetricians and Gynaecologists of Canada. Asymptomatic endometrial thickening // J. Obstet. Gynaecol. Can. 2010. Vol. 32. P. 990-999.

154.Yanoh K., Norimatsu Y., Hirai Y. New diagnostic reporting format for endometrial cytology based on cytoarchitectural criteria // Cytopatology. 2009. Vol. 20, N. 6. P. 388-394.

155.Yanoh K., Hirai Y., Sakamoto A. et al. New terminology for intrauterine endometrial samples: a group study by the Japanese Society of Clinical Cytology // Acta Cytol. 2012. Vol. 56, N. 3. P. 233-241.

156.Yilmaz S.A., Altinkaya S.O., Kerimoglu O.S. et al. The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions // J. Obstet. Gynaecol. 2017. Vol. 37, N. 1. Р. 58-63.

157.Zak H., Baranowski W. Cryoablation of endometrium in the treatment of pathological metrorrhagia // Pol. Merkur. Lekarski. 2005. Vol. 19, N. 113. P. 716-718.

158.Zhang Q., Qi G., Kanis M.J. et al. Comparison among fertility-sparing therapies for well differentiate earlystage endometrial carcinoma and complex atypical hyperplasia // Oncotarget. 2017 May 3. doi: 10.18632/oncotarget.17588.

159.Zhou H., Cao D., Yang J. et al. Gonadotropinreleasing hormone agonist combined with a levonorgestrelreleasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women // Int. J. Gynecol. Cancer. 2017. Vol. 27, N. 6. P.

1178-1182.

Медицинские книги

@medknigi